Serological biomarkers for acute mesenteric ischemia

Area of Science:

• Gastroenterology and Hepatology
• Vascular Surgery
• Biomarker Research

Background:

• Acute mesenteric ischemia (AMI) involves interrupted blood flow to visceral organs, causing severe metabolic distress.
• Timely diagnosis and intervention are critical for reducing high mortality rates associated with AMI.
• Current diagnostic methods lack specific biomarkers, necessitating further research into potential indicators.

Purpose of the Study:

• To review the etiology of Acute Mesenteric Ischemia (AMI).
• To discuss promising biomarkers for early AMI diagnosis, including I-FABP, a-GST, D-dimer, lactate, citrulline, ischemia-modified albumin, and PCT.
• To outline the current research landscape and future directions in AMI biomarker discovery.

Main Methods:

• Literature review of existing studies on AMI etiology and biomarkers.
• Analysis of current research on specific biomarkers such as I-FABP, a-GST, D-dimer, lactate, citrulline, ischemia-modified albumin, and PCT.
• Evaluation of the limitations and potential of these biomarkers in clinical practice.

Main Results:

• Several biomarkers, including I-FABP, a-GST, D-dimer, lactate, citrulline, ischemia-modified albumin, and PCT, show potential for early AMI diagnosis.
• Current clinical application of these biomarkers is limited due to small study populations and heterogeneity.
• Further research with larger, standardized patient cohorts is needed to validate these biomarkers.

Conclusions:

• Early diagnosis of AMI is crucial for successful treatment and reducing mortality.
• Biomarkers like I-FABP and lactate hold promise but require further validation.
• Future research should focus on larger, well-defined studies to establish reliable biomarkers for AMI.